GlassScriptPhysician profile
Stacy Newberry
NPI 1841775947
$28,154.23
in general payments reported to CMS, 2019-2025
30 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $436 · 2022: $727 · 2023: $5,494 · 2024: $5,993 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $3,653 · Travel and Lodging: $3,063 · Education: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,450.00 |
| Food and Beverage | $3,652.76 |
| Travel and Lodging | $3,062.59 |
| Education | $826.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,289.62 | 2021-2025 | Tagrisso, Datroway, Imfinzi |
| Daiichi Sankyo INC. | $4,561.20 | 2021-2025 | Datroway, Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $517.25 | 2022-2024 | Iclusig |
| Astellas Pharma US INC | $471.93 | 2022-2023 | |
| Janssen Biotech, INC. | $326.26 | 2021-2025 | Tecvayli, Carvykti, Talvey |
| Seagen INC. | $212.75 | 2021-2023 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $211.22 | 2021-2023 | Opdivo |
| Janssen Pharmaceuticals, INC | $200.88 | 2022-2023 | Xarelto |
| Incyte Corporation | $191.45 | 2022-2025 | Monjuvi |
| Lilly USA, LLC | $170.65 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $163.51 | 2023 | Libtayo |
| Pfizer INC. | $123.35 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.57 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $105.00 | 2022 | |
| Abbvie INC. | $68.31 | 2022-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $48.44 | 2025 | |
| Genzyme Corporation | $46.15 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $41.83 | 2021-2022 | |
| Celgene Corporation | $41.52 | 2021 | |
| Gilead Sciences, INC. | $36.34 | 2022-2023 | Trodelvy |
| Genentech USA, INC. | $31.04 | 2022-2023 | Tecentriq |
| Aveo Pharmaceuticals, INC. | $26.69 | 2021-2022 | |
| Pharmaessentia USA Corporation | $22.86 | 2023 | Besremi |
| Novo Nordisk INC | $21.58 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.24 | 2024 | Ultomiris |
| Genmab U.S., INC. | $19.90 | 2023 | Tivdak |
| Blueprint Medicines Corporation | $19.45 | 2024 | Ayvakit |
| Amgen INC. | $15.50 | 2021 | |
| Merck Sharp & Dohme LLC | $14.01 | 2023 | Keytruda |
| Kyowa Kirin, INC. | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Newberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.